As new medications enter the market, we’ve observed a troubling new trend: an influx of clinically superfluous brand drugs that carry hefty price tags but offer little to no added clinical value.
Recently, manufacturers have launched new brand-name prescription wound dressings that include similar combinations of ingredients as OTC and lower-cost generic products yet are priced far higher than the alternatives — up to 125 times more.
This report shines a spotlight on:
- What’s driving the increased need for wound care.
- The potential effects of high-cost prescription wound dressings on patients and plan sponsors.
- How Optum Rx helps improve the quality of care while lowering costs.
Related healthcare insights
Guide
New treatments for NASH, schizophrenia and more are on the way.
Article
New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.
